Spots Global Cancer Trial Database for refractory anaplastic large cell lymphoma

Every month we try and update this database with for refractory anaplastic large cell lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	NCT00939770	Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Anap... Refractory Mali... Refractory Neur...	Crizotinib Laboratory Biom... Pharmacological... Questionnaire A...	1 Year - 21 Years	Children's Oncology Group
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma	NCT03017820	B-Cell Non-Hodg... Histiocytic and... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Anapl... Recurrent Angio... Recurrent Mycos... Recurrent Plasm... Recurrent Prima... Recurrent T-Cel... Refractory Acut... Refractory Anap... Refractory Angi... Refractory Myco... Refractory Peri... Refractory Plas... Refractory Prim... Refractory T-Ce...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Positron Emissi... Recombinant Ves... Single Photon E... Cemiplimab	18 Years -	Mayo Clinic
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	NCT02978625	Adenoid Cystic ... Adnexal Carcino... Anaplastic Larg... Anaplastic Larg... Apocrine Carcin... Cylindrocarcino... Digital Papilla... Endocrine Mucin... Extramammary Pa... Extraocular Cut... Hidradenocarcin... Keratoacanthoma Malignant Sweat... Merkel Cell Car... Microcystic Adn... NK-Cell Lymphom... Papillary Adeno... Porocarcinoma Primary Cutaneo... Recurrent Matur... Recurrent T-Cel... Refractory Anap... Refractory Matu... Refractory Merk... Refractory Myco... Refractory Prim... Refractory Skin... Refractory T-Ce... Sezary Syndrome Signet Ring Cel... Skin Basal Cell... Skin Basosquamo... Skin Squamous C... Spiradenocarcin... Squamoid Eccrin... Squamous Cell C... Sweat Gland Car... Trichilemmal Ca... Vulvar Squamous...	Biopsy Biospecimen Col... Computed Tomogr... Laboratory Biom... Nivolumab Positron Emissi... Talimogene Lahe...	18 Years -	National Cancer Institute (NCI)
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin	NCT03278782	Recurrent Anapl... Recurrent Angio... Recurrent Matur... Recurrent Mycos... Recurrent Prima... Refractory Anap... Refractory Angi... Refractory Matu... Refractory Myco... Refractory Peri... Refractory Prim...	Pembrolizumab Romidepsin	18 Years -	M.D. Anderson Cancer Center
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma	NCT01590732	Mycosis Fungoid... Recurrent Anapl... Recurrent Angio... Recurrent Enter... Recurrent Hepat... Recurrent Perip... Refractory Anap... Refractory Angi... Refractory Ente... Refractory Hepa... Refractory Peri...	Carboplatin Etoposide Ifosfamide Romidepsin	18 Years -	M.D. Anderson Cancer Center
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma	NCT00939770	Recurrent Child... Recurrent Malig... Recurrent Neuro... Refractory Anap... Refractory Mali... Refractory Neur...	Crizotinib Laboratory Biom... Pharmacological... Questionnaire A...	1 Year - 21 Years	Children's Oncology Group
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas	NCT04774068	Recurrent Anapl... Recurrent Matur... Recurrent Prima... Recurrent Trans... Refractory Anap... Refractory Matu... Refractory Prim... Refractory Tran... T-Cell Non-Hodg...	Parsaclisib Romidepsin	18 Years -	Ohio State University Comprehensive Cancer Center
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	NCT02978625	Adenoid Cystic ... Adnexal Carcino... Anaplastic Larg... Anaplastic Larg... Apocrine Carcin... Cylindrocarcino... Digital Papilla... Endocrine Mucin... Extramammary Pa... Extraocular Cut... Hidradenocarcin... Keratoacanthoma Malignant Sweat... Merkel Cell Car... Microcystic Adn... NK-Cell Lymphom... Papillary Adeno... Porocarcinoma Primary Cutaneo... Recurrent Matur... Recurrent T-Cel... Refractory Anap... Refractory Matu... Refractory Merk... Refractory Myco... Refractory Prim... Refractory Skin... Refractory T-Ce... Sezary Syndrome Signet Ring Cel... Skin Basal Cell... Skin Basosquamo... Skin Squamous C... Spiradenocarcin... Squamoid Eccrin... Squamous Cell C... Sweat Gland Car... Trichilemmal Ca... Vulvar Squamous...	Biopsy Biospecimen Col... Computed Tomogr... Laboratory Biom... Nivolumab Positron Emissi... Talimogene Lahe...	18 Years -	National Cancer Institute (NCI)
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma	NCT03017820	B-Cell Non-Hodg... Histiocytic and... Myelodysplastic... Previously Trea... Recurrent Adult... Recurrent Anapl... Recurrent Angio... Recurrent Mycos... Recurrent Plasm... Recurrent Prima... Recurrent T-Cel... Refractory Acut... Refractory Anap... Refractory Angi... Refractory Myco... Refractory Peri... Refractory Plas... Refractory Prim... Refractory T-Ce...	Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Positron Emissi... Recombinant Ves... Single Photon E... Cemiplimab	18 Years -	Mayo Clinic
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas	NCT03598998	Anaplastic Larg... Nodal Periphera... Recurrent Anapl... Recurrent Angio... Recurrent Enter... Recurrent Folli... Recurrent Hepat... Recurrent Matur... Recurrent Monom... Recurrent Mycos... Recurrent Perip... Refractory Anap... Refractory Angi... Refractory Ente... Refractory Foll... Refractory Hepa... Refractory Matu... Refractory Myco... Refractory Peri... Subcutaneous Pa...	Pembrolizumab Pralatrexate	18 Years -	City of Hope Medical Center
Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL	NCT02572453	Recurrent Anapl... Recurrent Diffu... Recurrent Mantl... Recurrent Trans... Refractory Anap... Refractory Diff... Refractory Mant... Refractory Tran...	Onalespib	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: